Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Geographic Atrophy

Geographic Atrophy

Part of Age-Related Macular Degeneration

2 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Geographic Atrophy

20 trials tracked for Geographic Atrophy: 6 in phase 3 or 4 and 5 with published results. The most-cited published study has 495 citations.

20Trials tracked
6Phase 3 & 4
0Recruiting
5With published results
Phase distribution
Phase 3 6 Phase 2 10 Other / NA 4
  1. Phase 3 A Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration Completed · 495 cited
  2. Phase 3 Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration Completed · 492 cited
  3. Phase 3 Zimura in Participants With Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration Completed · 466 cited
  4. Phase 3 A Phase 3 Safety and Efficacy Study of Intravitreal Administration of Zimura (Complement C5 Inhibitor) Completed · 355 cited
  5. Phase 3 Phase 2/3 Study of ALK-001 in Geographic Atrophy Completed · 47 cited
  6. Phase 3 Avacincaptad Pegol Open-Label Extension for Patients With Geographic Atrophy Completed
Show 14 more trials
  1. Phase 2 Intravitreal LFG316 in Patients With Age-related Macular Degeneration (AMD) Completed
  2. Phase 2 Metformin for the Minimization of Geographic Atrophy Progression in Patients With AMD Completed
  3. Phase 2 OT-551 Antioxidant Eye Drops to Treat Geographic Atrophy in Age-Related Macular Degeneration Completed
  4. Phase 2 Clinical Study to Investigate Safety and Efficacy of GSK933776 in Adult Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration Completed
  5. Phase 2 CLG561 Proof-of-Concept Study as a Monotherapy and in Combination With LFG316 in Subjects With Geographic Atrophy (GA) Completed
  6. Phase 2 Study of Pegcetacoplan (APL-2) Therapy in Patients With Geographic Atrophy Completed
  7. Phase 2 Sirolimus for Advanced Age-Related Macular Degeneration Completed
  8. Phase 2 A Study of NGM621 in Participants With Geographic Atrophy Completed
  9. Phase 2 A Study of Lampalizumab Intravitreal Injections Administered Every Two Weeks or Every Four Weeks to Participants With Geographic Atrophy Completed
  10. Phase 2 A Study to Evaluate the Safety and Clinical Response of Subretinal Administration of CNTO 2476 in Participants With Geographic Atrophy Completed
  11. N/A Subthreshold Laser Treatment for Reticular Pseudodrusen and Geographic Atrophy Secondary to AMD Completed
  12. N/A Evaluation of the Precision of the Microperimetry Function of the Spectral OCT/SLO Completed
  13. N/A Cirrus HD-OCT Measurement of Area of Increased Light Penetration Under the Retinal Pigment Epithelium (RPE) Completed
  14. N/A Patients With Geographic Atrophy and Their Patient Journey in the United States (US) Completed

Showing the 20 most-cited and recently-updated of 20 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

Geographic Atrophy: what the trials found

Avacincaptad pegol has demonstrated a statistically significant reduction in geographic atrophy (GA) area as measured by fundus autofluorescence (FAF) 3. Additionally, multiple time-point analyses of the mean rate of growth (slope) for GA area using FAF showed significant results at both 3 time points (p=0.0064) and 5 time points (p=0.0165) 5.

APL-2 demonstrated a statistically significant reduction in the total area of GA lesions at month 12 (p=0.0004) and month 24 (p<0.0001) across two separate trials [2, 4]. One trial also showed a significant mean change in the total area of GA lesions through month 24 (p=0.0007) 4.

Avacincaptad pegol did not show statistically significant changes in best corrected visual acuity (BCVA) at 24 months (p=0.58) 5 or other visual acuity measures including low luminance BCVA (p=0.8405) 3.

Recent results — preliminary, needs further review

  • NGM621 showed no significant change in the rate of GA lesion area 7.
  • The trial for ALK-001 oral capsule did not report specific outcome values.

For the clinician treating this condition

  • Avacincaptad pegol is associated with a statistically significant reduction in GA lesion size as measured by FAF [3, 5].
  • APL-2 demonstrated significant reductions in total GA lesion area at both the 12-month and 24-month marks [2, 4].
  • Clinical improvements in GA lesion size with Avacincaptad pegol or APL-2 were not consistently associated with statistically significant changes in BCVA [3, 5].

AI synthesis of 4 cited trials, updated Jun 26, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Central 2.50-mm geographic atrophy extent correlates with visual function measures in age-related macular degeneration
Ophthalmology RCT
Central 2.50-mm geographic atrophy extent correlates with visual function measures in age-related macular degeneration Central vision loss impacts daily life for geographic atrophy patients
This observational analysis of Phase III clinical trial data involved 856 individuals aged 50 years or more with bilateral geographic atroph…
New analysis shows that damage in the very center of the eye most affects how people with geographic atrophy experience their daily lives.
Aug 4, 2026
Avacincaptad pegol reduces geographic atrophy growth compared to sham in Age-Related Macular Degeneration patients
Drug Pipeline RCT
Avacincaptad pegol reduces geographic atrophy growth compared to sham in Age-Related Macular Degeneration patients This Eye Injection Slows Blindness for Two Years Straight
This phase 3, randomized, sham-controlled study evaluated avacincaptad pegol in patients with non-center point-involving geographic atrophy.
For patients with a leading cause of blindness, this treatment offers lasting protection without new side effects.
Apr 24, 2026